2025 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook: Key Indicators Shaping Growth Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Market Size Be by 2025?
In recent times, the market for phosphoinositide 3-kinase (PI3K) inhibitors has witnessed a substantial growth. It is projected to expand from $1.38 billion in 2024 to $1.56 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.8%. The acceleration in growth during the historic period is due to factors like the rising incidence of cancer, an increase in targeted therapy research, approvals for first-generation PI3K inhibitors by regulatory bodies, growing healthcare spendings, and the broadening scope of clinical trials for hematologic malignancies.

What's the Long-Term Growth Forecast for the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size Through 2029?
Rapid expansion is anticipated in the phosphoinositide 3-kinase (PI3K) inhibitors market size in the coming years. The market is expected to surge to "$2.55 billion by 2029" with a compound annual growth rate (CAGR) of 13.2%. The projected growth can be ascribed to factors like the rising demand for combination treatments, the development of next-generation PI3K inhibitors exhibiting enhanced safety measures, increased funding in cancer research and development, extending applications beyond oncology, and the growing utilization of biomarkers for patient selection. During the forecast period, notable trends encompass a shift towards dual and pan-isoform PI3K inhibitors, an escalating preference for oral methods over intravenous techniques, an amplifying emphasis on combating resistance processes, an increasing integration of artificial intelligence within drug discovery, and an enlarging involvement of PI3K inhibitors in immunotherapy combinations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/phosphoinositide-3-kinase-pi3k-inhibitors-global-market-report

What Are the Key Growth Drivers Fueling the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Expansion?
The escalating occurrence of cancer and autoimmune diseases is projected to spur the expansion of the phosphoinositide 3-kinase (PI3K) inhibitors market in the future. Cancer constitutes a range of illnesses marked by unchecked cellular growth and expansion, while autoimmune diseases occur when the body's internal defense mechanism erroneously goes after its healthy tissues, resulting in sustained inflammation and tissue destruction. The rising frequency of cancer and autoimmune diseases can be attributed to a growing genetic predisposition that instigates accumulated genetic mutations and disruptions in the immune system over time. Phosphoinositide 3-Kinase (PI3K) inhibitors play a crucial role in managing the increasing prevalence of these diseases by targeting deviant PI3K signaling, a known factor in tumor development and immune malfunction. This approach provides medical benefits by leveraging precision medicine strategies to improve treatment effectiveness and patient prognosis. For example, the National Cancer Institute, a US government agency, reported in May 2024 that the number of cancer survivors in the US was 18.1 million in 2022 and this figure is anticipated to reach 22.5 million by 2032. They estimate that 40.5% of the population may face a cancer diagnosis in their lifetimes. Consequently, the surge in instances of cancer and autoimmune diseases is fueling the growth of the Phosphoinositide 3-Kinase (PI3K) inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23474&type=smp

What Long-Term Trends Will Define the Future of the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market?
Key players in the phosphoinositide 3-kinase (PI3K) inhibitors market are diligently working towards the creation of novel solutions, such as PI3K delta inhibitor treatments, to cater to ailments tied to imbalanced phosphoinositide 3-kinase (PI3K) signaling. Therapies involving PI3K delta inhibitors are highly targeted treatments that impede the PI3K delta enzyme, a critical player in immune cell signaling, resulting in decreased inflammation, autoimmune reactions, and specific blood malignancies. For example, in March 2023, Joenja (leniolisib) received the endorsement from the US Food and Drug Administration (FDA), marking it as the first-ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in individuals who are 12 years and above. This authorization denoted a remarkable advancement in the realm of targeted therapies by integrating a precision medicine methodology to tackle immune disorder caused by gene mutations in either PIK3CD or PIK3R1. The introduction of Joenja (leniolisib) not only broadens the therapeutic reach of phosphoinositide 3-kinase (PI3K) inhibitors beyond cancer but also highlights an increasing emphasis on custom-made treatments tailored for unusual immune disorders.

How Is the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmented?
The phosphoinositide 3-kinase (pi3k) inhibitors market covered in this report is segmented -

1) By Type Of Inhibitor: Isoform Selective Inhibitors, Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors, Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors, Novel Targeted Inhibitors
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
3) By Application Areas: Cancer Treatment, Metabolic Disorders, Autoimmune Diseases, Neurological Disorders
4) By End User: Hospitals, Research Institutes, Pharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:
1) By Isoform Selective Inhibitors: Phosphoinositide 3-Kinase Alpha (PI3Ka), Phosphoinositide 3-Kinase Beta (PI3Kß), Phosphoinositide 3-Kinase Delta (PI3Kd), Phosphoinositide 3-Kinase Gamma (PI3K?)
2) By Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors: Class I Phosphoinositide 3-Kinase (PI3K), Non-Isoform Specific Phosphoinositide 3-Kinase (PI3K), Phosphoinositide 3-Kinase Kinase Domain
3) By Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target of Rapamycin (mTOR) Inhibitors: Phosphoinositide 3-Kinase (PI3K) and Mechanistic Target of Rapamycin (mTOR) Inhibition, Adenosine Triphosphate-Competitive Dual Inhibitors, Allosteric Dual Inhibitors
4) By Novel Targeted Inhibitors: Next-Generation Phosphoinositide 3-Kinase, Targeting Mutant Phosphoinositide 3-Kinase Isoforms, Autophagy Modulators, Checkpoint Inhibitors, Combination Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23474&type=smp

Which Companies Are Leading the Charge in Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Innovation?
Major companies operating in the phosphoinositide 3-kinase (PI3K) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Boehringer Ingelheim, Genentech Inc., Incyte Corporation, Exelixis, Kura Oncology, TG Therapeutics Inc., Verastem Oncology

Which Regions Are Leading the Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market in Revenue?
North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phosphoinositide 3-kinase (PI3K) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23474

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.